Index

abnormal states, 4–5
ACE (angiotensin converting enzyme) inhibitors, 24, 76, 82, 117, 120
adverse drug reactions, 31–45, 48–61, 194–209
adverse event, definition, 194, 196–201
Altman-Bland plot, 328–29, 332
American Academy of Family Practice Guidelines, 103
American College of Physicians, 292
ANCOVA modeling, 81
angiotensin converting enzyme (ACE) inhibitors, 15, 76
antiarrhythmic drugs, 59
antibodies, 48
anticoagulation, 106–7, 133, 230–40
antiepileptic medications, 49
antihypertensive medications, 21, 55, 64, 117
anxiety and monitoring, 141–46
Aronson, Jeffrey K., 3–14, 31–47, 48–62
arthritic symptoms, 66
aspirin, initial monitoring, 76
asthma
monitoring measurements, 56(t), 76, 149
options and decision making, 16(t), 20(t)
pathophysiology of, 53(t), 57–58
self-monitoring, 124–26, 132–33
testing frequency, 25
asymptomatic period, 5
Australian Antibiotic Guidelines, 118
Australian National Health and Medical Research Council (NHMRC), 134
Australian National Heart Foundation, 246
azathioprine, 82
B-type natriuretic peptide (BNP), 5
basal-bolus regimen, 221
Bayesian Model, 85–86, 119
Bedson, J., 335–56
behaviour, effects of monitoring, 140–51
Bell, Katy, 75–89
benefits, patient, 7, 31–45
beta-blockers, 76, 117
Binnekade, J.M., 313–24
bioequivalence, 79
biological variability, 22, 110
biomarkers, 34, 38, 45, 48–61, 76–85
biomarkers and control charts, 92–93
biosignals, 314–15, 322
biphasic, concentration-effect curve, 39(t)
bisphosphonates, 84–85
Bland-Altman, 70, 81, 328–9, 332
blood coagulation, 230–31. See also INR
blood concentration measurement control charts, 92–93
factors of adherence, 124–26
high-risk groups and monitoring, 109–11
ICU, 315–17
pharmacokinetic process, 34–35
self-monitoring, 45, 132–33
blood glucose concentrations ICU, 318–22
intervals and disease, 107–9
monitoring, 213–27
schedule of monitoring, 128–29
blood inflammatory markers, 48
blood pressure. See also hypertension
ACE inhibitor and changes, 120
control charts, 95–96
diastolic, measuring, 96–98
low-dose therapy, 117
monitoring, 20, 22, 64
pre-eclampsia, 305–10
raised, 213–27
blood samples, 176, 214–17
(BNP) B-type natriuretic peptide, 5
bone metabolism, 256–58, 276–79
Bossuyt, Patrick M.M., 158–65, 313–24
breast cancer, 18
C reactive protein (CRP), 278–79
carbimazole treatment, 5, 18
carcinoembryonic antigen, 55, 57
cardiac failure, ischaemic, 37–38
cardiac glycosides, 35–41
cardiometabolic disease, primary
hypothyroidism, 258, 265, 276–78
CD (critical difference) values, 90–91, 264, 267–76
centralized laboratory testing (CLT), 174–77
cervical cancer, 15, 17, 132
Index

358  cervical screening, 26
charts, control, 90–101
CHD (coronary heart disease), 278–79
chemotherapy, 59
chest computed tomography (CT), 18, 163
chest X-ray, 48
cholesterol
changes, 9, 85–87
modifying interventions, 245–52
serum cholesterol concentration, 55, 67, 251
synthesis, 107–9
choosing a test, criteria for, 19
chromatography, high-performance liquid, 60
chronic conditions, 3, 11, 127, 146–49, 325, 340–50
ciclosporin concentrations, 60
clinical endpoints. See surrogate endpoints
clinical measurements, 9, 75–88
Clinical Pathology Accreditation UK, 169
clinical trial, 18
clozapine-induced neutropenia, 206
CLT (centralized laboratory testing), 174–77
collateral effects, 11
colorectal cancer, 18
congestive cardiomyopathies, 37
dose and effects, 10–11, 37–41
dose-response curve, 37–41, 197–205
drug therapy, 33–41
drugs, adverse effects, 31–45, 48–61, 194–209
DVT (deep-vein thrombosis), 233
ehocardiography, 52
effects, adverse, see also adverse drug reactions, 10–11, 106
emotional response, 43–45
enalapril, 59
epidemiological study, US, 41, 304–5
erthrocyte membranes, 39–41, 107
erthromycin, 31
estrogen receptor status, 82
EWMA (exponentially weighted moving average), 95, 98–99
Farmer, Andrew J., 103–13, 213–28
Ferner, Robin E., 194–210
folate supplementation, 76
formulations with outcome measures, 77(t)
Gansevoort, R.T., et al, 309
Gastrointestinal bleeding, 59
Gastrointestinal tract, 32
GFR (glomerular filtration rate), 291–99
Glasziou, Paul, 3–14, 63–74, 114–22, 245–53
Glaucoma, intraocular pressure, 325–34
Glaucoma, monitoring tests, 66, 69, 72
Glomerular filtration rate (GFR), 291
Glucose monitoring, 318–22
Glycaemic control, monitoring, 106, 213–27
delivering tests, 171–77
depression, 76, 142–43, 146–50
diabetes mellitus
   glucose metabolism, 318–21
   measuring schedule, 106–9
   monitoring, 45, 63–65, 213–27
testing, 181–83
diagnostic tests, 18
dichotomous events, 67
Dinamap Pro, 307
disease management
   history, natural, 63–64
   options for changing treatment, 116–17
surrogate endpoints, 54(t)
distal tests, 21
Doppler ultrasound, 305
dose and effects, 10–11, 106
dose-response curve, 37–41, 197–205
drugs, adverse effects, 31–45, 48–61, 194–209
DVT (deep-vein thrombosis), 233
delivery, tests, 171–77
depression, 76, 142–43, 146–50
diabetes mellitus
   glucose metabolism, 318–21
   measuring schedule, 106–9
   monitoring, 45, 63–65, 213–27
testing, 181–83
diagnostic tests, 18
dichotomous events, 67
Dinamap Pro, 307
disease management
   history, natural, 63–64
   options for changing treatment, 116–17
surrogate endpoints, 54(t)
distal tests, 21
Doppler ultrasound, 305
dose and effects, 10–11, 106
dose-response curve, 37–41, 197–205
drugs, adverse effects, 31–45, 48–61, 194–209
DVT (deep-vein thrombosis), 233
echocardiography, 52
effects, adverse, see also adverse drug reactions, 10–11, 106
emotional response, 43–45
enalapril, 59
epidemiological study, US, 41, 304–5
erthrocyte membranes, 39–41, 107
erthromycin, 31
estrogen receptor status, 82
EWMA (exponentially weighted moving average), 95, 98–99
Farmer, Andrew J., 103–13, 213–28
Ferner, Robin E., 194–210
folate supplementation, 76
formulations with outcome measures, 77(t)
Gansevoort, R.T., et al, 309
gastrointestinal bleeding, 59
gastrointestinal tract, 32
GFR (glomerular filtration rate), 291–99
Glasziou, Paul, 3–14, 63–74, 114–22, 245–53
glaucoma, intraocular pressure, 325–34
glaucoma, monitoring tests, 66, 69, 72
glomerular filtration rate (GFR), 291
glucose monitoring, 318–22
glycaemic control, monitoring, 106, 213–27

D’Assunção, Jefferson, 325–34
deep-vein thrombosis (DVT), 233

Craig, Jonathan, 75–89, 286–302
glycosylated haemoglobin (HbA1c), 5, 107, 217–19
Gram-negative septicaemia, 57
Hashimoto's thyroiditis, 254–55
HbA1c (glycosylated haemoglobin), 5, 107, 217–19
Healey, Paul R., 325–34
heart disease, 49, 67
Heidelberg retinal tomography (HRT), 327
Heneghan, Carl, 123–39, 229–44
hepatic disease, 10, 18
Heritier, Stephane, 245–53
heterogeneous diseases, 337
Hill, Austin Bradford, 57–58
HIV infections, 144, 163
home care, 179–92
Hormesis, 40(t), 41
Horvath, Andrea Rita, 254–85
HPV (human papilloma virus), 132, 144–45
HRT (Heidelberg retinal tomography), 327
human papilloma virus (HPV), 132, 144–45
hydralazine, 59
hyperkalaemia, 15
hypersusceptibility drug reactions, 11, 82, 205
hypertension. See also blood pressure
clinitian-led monitoring, 20, 130–31
effects of treatment, 64–68
patient response, 144–49
pre-eclampsia, 305–7, 310
preventive therapies, 49
stepped care, 10, 116–17
hyperthyroidism, 18, 32, 37
hypertrophic cardiomyopathy, 37
hypoglycaemia, 45, 319–21
hypothyroidism, levothyroxine replacement, 254–79
ICU (intensive care unit), 313–22
illness and treatment pathway, 20(t), 22
Illness Perceptions Questionnaire (IPQ), 147
indicators, health or illness, 123–34
individual monitoring, 195–205
individual time spent in the target range (ITTR), 236–37
information technology (IT) management, 161–75
INR (international normalized ratio), 6, 8, 11, 25, 101
monitoring, 180, 182, 188–89, 206
testing, 11, 26, 111(t), 114–15, 124
insulin injections, 45, 162, 321–22
intensive care, monitoring, 313–21
intensive care unit (ICU), 313–22
international normalized ratio (INR), 6, 8, 11, 25, 101
interventions, behavioural, 3–4, 41–45
IPQ (Illness Perceptions Questionnaire), 147
isosorbide, 59
IT (Information Technology) management, 161–75
ITTR (individual time spent in the target range), 236–37
joint pain, 337–38, 347–50
kidney graft function, monitoring, 287–89
Kimmel, A.D., 163
knee osteoarthritis, 335–51
laboratory measures, 75–88
laboratory monitoring, 166–77
Laopaiboon, Malinee, 303–12
levothyroxine, replacing, 254–79
lipid profiles, 245–47
lithium concentrations, 18, 64, 109, 207
loop diuretics, 15, 40(t), 41
Lumbiganon, Pisek, 303–12
Macaskill, Petra, 90–102, 325–44
magnetic resonance imaging (MRI), 337, 340
managing information technology (IT), 161–75, 238
Mant, David, 15–30
McCaffery, Kirsten, 123–39, 140–57
MCID (minimum clinically important difference), 342–49
MDRD (Modification of Diet in Renal Disease), 292
measurement errors, 22
Medical Outcomes Survey Short Form, 150
Medical Research Council, UK, 7
Michie, Susan, 31–47, 123–39, 140–57
minimum clinically important difference (MCID), 342–49
mixed-effects models, 78–79
Modification of Diet in Renal Disease (MDRD), 292
monitoring
effectiveness and costs, 158–64
frequency, 106–10
Index

monitoring (cont.)
  high-risk groups, 109–10
  interventions, 26–27
  long-term, 90–101
  measurement errors, 84–85
  problems, 12, 27, 194–209
  response, initial, 75–88
  schedule development, 6–8, 103–13
  strategies, 8–10, 24–29, 38–41
  tests, choosing, 3–6, 19–22, 23(t), 34(t), 63–74, 173
  tools, learning and motivational, 11–12, 31–45, 123–34
  Monte Carlo approaches, 163
  MR (moving range), 95
  MRI (magnetic resonance imaging), 337, 340
  myocardial contractility, tissue effects, 35–37
  myocardial infarctions, 67, 82
  NACB (National Academy of Clinical Biochemistry), USA, 269–71
  National Academy of Clinical Biochemistry (NACB), USA, 268–71
  National Health Service, UK, 169, 245
  National Service Frameworks, UK, 172
  natriuretic effects, 41
  natural history of diseases, 63–64, 72
  neurological changes, 213–27
  neutropenia, 5, 109, 206
  nitric oxide, exhaled, 9
  NNT (number needed to treat), 21
  non-steroidal anti-inflammatory drug (NSAID), 338, 347–49
  Nonesuch Shale, 49
  NSAID (non-steroidal anti-inflammatory drug), 338, 347–49
  number needed to treat (NNT), 21
  obesity, 339, 349
  OCT (optical coherence tomography), 327
  oncology, clinical, 50(t), 51
  optic neuropathy, 325–27
  optical coherence tomography (OCT), 327
  oral administration, 34
  oral anticoagulation therapy, 229–43
  osteoarthritis, monitoring, 86, 335–56
  osteoporosis, measurement errors, 84–85
  ovarian carcinoma, 57, 146
  overdose, risk of, 49
  Oxfordshire, 245
  Pap (Papanicolaou) smear, 15, 144–45
  PASS (patient acceptable symptom state), 345
  pathogenesis, biomarkers of, 54–58
  pathophysiological pathways, 38, 53–54, 326
  pathophysiology of diseases, 31–45
  patient acceptable symptom state (PASS), 345
  patient benefits, 7
  patients’ preferences, 145–46
  peak expiratory flow (PEFR), 60, 133
  Peat, G, 335–56
  PEFR (peak expiratory flow), 60, 133
  Perera, Rafael, 229–44
  personalized treatment assessments (PTAs), 133
  pharmacodynamic effects, 10–11, 21, 33–41, 120
  pharmacokinetics, 10, 21, 33–41, 116–21
  physiological consequences, 313–21
  plasma concentrations, 26, 49, 51, 320
  plasma proteins, 34
  pneumonia, 31, 48
  POCT (point-of-care testing), 22, 167–77, 179–91, 240, 320
  Polypill approach, 10
  population monitoring, 200–203
  Porcheret, M., 335–56
  postmenopausal women, 84–85
  potassium depletion, 37
  pre-eclampsia, monitoring, 303–10
  pregnancy, monitoring, 303–11
  Price, Christopher P., 179–93
  Primary Care Contract, UK, 172
  prothrombin time, abnormal, 5
  proximal-distal, 20–21
  psychodynamics, 41–45
  psychological issues
    benefits and harms, 141–44
    decision-making approaches, 144–46
    effects of monitoring, 140–41
    explanations and treatments, 123–34
    regimens and outcomes, 146–51
    social implications, 140–57
    psychometric questionnaire (ThyTSQ), 266
  PTAs (personalized treatment assessments), 133
  pulmonary artery pressure, 5, 317
  pulmonary embolism, 107
QALYs (quality-adjusted life years), 160, 163
QOL (quality of life), 141, 143, 150
quality-adjusted life years (QALYs), 160, 163
quality of life (QOL), 141, 143, 150
radioimmunoassay, 60
RCTs (randomized control trial), 18, 161–64
RCV (reference change value), 90–91
reference change value (RCV), 90–91
regular measurements, schedule of, 6–7(t)
renal disease and transplantation, 10, 286–300
results, idiosyncratic, 106
risk information and monitoring, 126
run chart, 94–96
sample cycle, 166–69
scanning laser polarimetry (SLP), 327
screening strategy, 15, 18
self-monitoring tests
  blood glucose, 227
  choosing, 73
  feedback, 148–50
  frequency and treatment, 106–12
  oral anticoagulation therapy, 240–42
  osteoarthritis, 346–49
  psychological factors, 22, 27, 45, 73, 123–34
  warfarin therapy, 119(t)
serum cholesterol concentration, 55, 67, 251
serum drug concentrations, 34, 91–92
serum electrolyte concentrations, measurement, 15, 18
serum thyroid hormone concentration, 32
serum UDP-galactosyl, 51
Shewhart, W.A., 92, 93, 95–96
side effects, see also adverse drug reactions, 195
signal-to-noise ratio, 22, 67–69
SLP (scanning laser polarimetry), 327
Smellie, W. Stuart A., 166–78
SMR (standardized mortality ratio), 322
social and psychological implications, 140–57
social cognitive theory, 43
social rewards, 43–45
SPC (statistical process control), 86–87, 92
sputum, 48
standardized mortality ratio (SMR), 322
statistical process control (SPC), 86–87, 92
Stevens–Johnson syndrome, 196
stress and preventing disease, 129–30
strokes, 49, 52, 67
surrogate endpoints, 48–61
surrogate markers, 6, 34, 104–6, 160
Swan–Ganz catheters, 6, 313
systemic circulation, 34
testing, interval, 4–5, 8(t)
testing frequency, 25
tests. See also self-monitoring tests; specific tests
  over-the-counter, 123–24
  responsivity to monitoring, 21, 63–74
therapeutic interventions
  action mechanisms, 31–45
  monitoring, 26, 48–61
thiazide diuretic, 15, 40(t), 41
thiopurine methyltransferase (TPMT), 60, 83
thromboembolic complications, 229, 235–41
thrombolysis, 82
thyroid function, 106, 256–68
thyroid peroxidase (TPO), 254, 268
thyroid stimulating hormone (TSH), 32, 254–79
thyrotrophin-releasing hormone (TRH) test, 261–62, 267
time spent in the target range (TTR), 235–41
TMPT (thiopurine methyltransferase), 60, 82–83
toxic therapeutic ratio, 35
toxicity
  dose relation, 205–6
  effects, 11, 49
  monitoring pharmacokinetics, 195, 202–5
  renal function, 289–90
TPMT (thiopurine methyltransferase), 60, 82–83
TPO (thyroid peroxidase), 254, 268
treatment
  adjusting and options, 8, 114–22
  initial response, 75–88
TRH (thyrotrophin-releasing hormone) test, 261–62, 267
TSH (thyroid stimulating hormone), 32, 254–79
TTQA (training, technology, quality assurance), 27–29
TTR (time spent in the target range), 235–41
Index

tumour markers, 51

typhoid, 48

vascular changes, 213–27, 290

vasodilators, 59

venous thromboembolism, 39(t)

ventricular arrhythmias, 59

ventricular fibrillation, 5

viral diseases, 48

vitamin K, 230–37

Ward, A., 335–56

warfarin, 11, 26, 118–19, 119(t), 229–43

weight management, 141–44

Western Electric Company (WECO), 12, 97

Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), 340–45

whole blood drug concentrations, 34

Wisconsin Alumni Research Foundation, 229

WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index), 340–45

World Health Organization, 126

publication, 148, 305

X chart, 95, 98–99

X-ray, chest, 48